Menu Search
Equities

Mauna Kea Technologies SA

0P5I:LSE

Mauna Kea Technologies SA

Actions
  • Price (EUR)0.270
  • Today's Change0.270 / --
  • Shares traded3.00
  • 1 Year change--
  • Beta--
Data delayed at least 20 minutes, as of Nov 06 2024 11:14 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Mauna Kea Technologies SA formerly Mauna Kea Technologies SAS is a France-based medical device manufacturing company. The Company specializes in designing, developing, and selling optical biopsy devices and tools. Its products are intended for visualizing and detecting cellular abnormalities during the gastrointestinal and pulmonary endoscopic procedures, primarily in cancer patients. It provides Cellvizio product that is used by medical specialties and is revolutionizing the way physicians diagnose and treat patients making a transformative change in medicine. Its real-time in vivo cellular imaging platform, that delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time.

  • Revenue in EUR (TTM)7.54m
  • Net income in EUR-11.21m
  • Incorporated2000
  • Employees65.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.